Home Sectors Healthcare Recent Trend: Repligen Corporation (NASDAQ: RGEN)

Recent Trend: Repligen Corporation (NASDAQ: RGEN)


Repligen Corporation is part of the healthcare sector and biotechnology industry. The company CEO is Tony J. Hunt. Repligen Corp is a bioprocessing company developing, producing and commercializing biologic drugs. The company offers its products to life science companies, global biopharmaceutical companies, and contract manufacturers worldwide.

Previous Intraday Trading Performance:

The RGEN stock showed a previous change of -1.45% with an open at 76.45 and a close of 74.98. It reached an intraday high of 77.05 and a low of 74.57.

SeekingAlpha:  How To Find The Best Growth Stocks


The stock has a market cap of $3.6b with 48.0m shares outstanding, of which the float is 45.5m shares. Trading volume reached 238,211 shares compared to its average volume of 442,387 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Repligen Corporation shares returned -0.45% and in the past 30 trading days it returned 14.04%. Over three months, it changed 27.82%. In one year it has changed 68.91% and within that year its 52-week high was 77.91 and its 52-week low was 43.02. RGEN stock is 74.29% above its 52 Week Low.

Our calculations show a 200 day moving average of 59.71 and a 50 day moving average of 65.68. Currently RGEN stock is trading 25.58% above its 200 day moving average.

SeekingAlpha:  How To Find The Best Growth Stocks


The last annual fiscal EPS for the company was reported at 0.37 that ended on 31st of December 2018, which according to the previous close, that is a PE of 202.65. Based on 5 analyst estimates, the consensus EPS for the next quarter is 0.20. The TTM EPS is 0.74, which comes to a TTM PE of 101.32. Historically, the PE high was 202.65 and the PE low was 23.90. If the stock reached its PE low, that would represent a price of 17.69, which is a decrease of -76.41%.

Below was the last reported quarterly diluted earnings per share:

1stQtr of 2019 (Reported on 05/09/2019): 0.17
4thQtr of 2018 (Reported on 02/21/2019): 0.12
3rdQtr of 2018 (Reported on 11/01/2018): 0.10
2ndQtr of 2018 (Reported on 08/02/2018): 0.06
1stQtr of 2018 (Reported on 05/08/2018): 0.08

Base on our calculations, the intrinsic value per share is 22.18, which means it may be overvalued by -238.08%.

Indicators to Watch:

The current calculated beta is 0.97.

SeekingAlpha:  Microcaps mostly among midday movers

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 3.63%, return on assets is 2.88%, profit margin is 10.21%, price-to-sales is 17.40 and price-to-book is 5.84.

Company Scores:

All scores are out of six:
 0  :Valuation Score
 1  :Past Performance Score
 5  :Financial Strength Score
 4  :Future Growth Score
 0  :Dividend Score
 2  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.